Aratana lands fourth FDA approval
Aratana Therapeutics Inc. landed its fourth FDA approval Friday. The company was granted a label extension of Nocita to alleviate postoperative pain for cats after a declawing procedure.
Aratana (Nasdaq: PETX) first received approval for the product in 2016 to be used in dogs after knee surgery. The product is also similar to a bupivacaine, a local anesthetic used in humans.
Nocita brought Aratana $1.8 million in sales in the quarter ending June 30, and $2.8 million in all of 20 17 — the product's…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Elise Reuter Source Type: news